Between the two, semaglutide and tirzepatide consistently lead the clinical data, and the right choice usually depends on BMI, metabolic history, and how the body responds to the starting dose
Here's the thing - if you're on TRT and you're still following generic cutting advice, you're leaving a serious advantage on the table
As of April 15, 2026, it has been removed from the FDA's Category 2 list, with PCAC review scheduled for July 24, 2026 to determine its compounding status
Your routine stays simple and your skin responds predictably
Whether you are using a copper peptide serum for facial rejuvenation, subcutaneous injections for systemic benefits, or exploring oral options for convenience, the right dose exists for your specific situation
EEG recordings were analyzed according to Rechtschaffen and Kales standardized criteria